175 results for "posttraumatic stress"
State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
Journal of Traumatic Stress – March 12, 2026
Summary
MDMA-assisted psychotherapy has shown remarkable promise for treating posttraumatic stress disorder (PTSD), with response rates exceeding 60% and remission rates around 40% in recent trials involving over 300 participants. Despite these encouraging results, the U.S. Food and Drug Administration denied market approval in August 2024 due to concerns about evidence gaps. This review highlights methodological limitations, such as blinding challenges and a lack of active comparators, while suggesting future research should integrate MDMA with established trauma-focused therapies to enhance cognitive behavioral outcomes.
Abstract
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combine...
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes
European Neuropsychopharmacology – March 12, 2026
Summary
MDMA-assisted therapy shows promise for reducing PTSD symptoms, with a notable effect size of -1.19 across nine trials involving 298 participants. Additionally, it may alleviate dissociative symptoms (effect size -0.37) and enhance overall functioning (effect size -0.83). However, the evidence is limited, as most studies faced high bias risks and small sample sizes. Overall certainty in findings remains low, emphasizing the need for larger, more rigorous trials to fully understand MDMA-AT's potential benefits in treating PTSD.
Abstract
Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to...
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review
American Journal of Health-System Pharmacy – March 04, 2026
Summary
MDMA and ketamine IV show significant promise for treating posttraumatic stress disorder (PTSD), with studies indicating that around 60% of participants experience symptom improvements under supervised conditions. These treatments are generally well tolerated, yet interpretations must consider factors like treatment expectancy and blinding issues. While MDMA and ketamine lead the way in efficacy, randomized controlled trials on other psychedelics, such as psilocybin, are essential to evaluate their potential benefits in clinical psychology and psychiatry for PTSD management.
Abstract
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under ...
Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder: Targeting Complementary Neurobiological Mechanisms.
The Nursing clinics of North America – March 01, 2026
Summary
A compelling rationale exists for combining Ketamine and Prazosin to treat co-occurring Posttraumatic stress disorder (PTSD) and Alcohol use disorder (AUD). Ketamine offers rapid PTSD symptom reduction and AUD relapse prevention, while Prazosin targets nightmares and may curb alcohol intake. Their distinct neurobiological mechanisms—modulating glutamatergic neurotransmission and attenuating noradrenergic hyperactivity—make combination pharmacotherapy promising. This strategy could improve patient stabilization and readiness for therapy. Nurse practitioners are exploring its safety and efficacy for integrated care.
Abstract
Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Keta...
Ketamine as a Mental Health Treatment
AJN American Journal of Nursing – February 19, 2026
Summary
Ketamine shows remarkable promise for treating treatment-resistant depression, anxiety, and PTSD, with a clinical trial involving over 1,500 participants demonstrating significant improvements in symptoms. Initially approved as an anesthetic in 1970, the FDA sanctioned esketamine (Spravato) for major depressive disorder in 2019. Various administration methods, including intranasal and IV infusions, offer flexibility but also raise regulatory challenges. As mental health needs surge globally, understanding ketamine's role is crucial for healthcare professionals guiding patients through this evolving treatment landscape.
Abstract
Ketamine has emerged as a promising intervention for treatment-resistant mental health disorders, such as depression, anxiety, and posttraumatic st...
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review.
Clinical psychology review – February 02, 2026
Summary
Ketamine-assisted psychotherapy significantly enhances treatment engagement and symptom reduction for various psychiatric disorders, including depression and PTSD. A systematic review of 72 studies (from 64 articles) explored this promising approach. While only 11 were randomized controlled trials, and just two randomized psychotherapy within ketamine treatment, clinical effects were generally positive. However, current evidence does not definitively support added benefits from psychotherapy itself or synergy, highlighting the need for more controlled trials.
Abstract
Ketamine-assisted psychotherapy (KAP) is considered a promising treatment strategy in psychiatric disorders, combining psychotherapeutic interventi...
A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program
Journal of Military Veteran and Family Health – February 01, 2026
Summary
Combining sublingual ketamine therapy with an intensive outpatient program shows promise for Veterans facing comorbid mental health conditions. In a cohort of 56 participants, significant reductions in anxiety and depression symptoms were observed, particularly among those with moderate to severe initial symptoms. Additionally, quality of life scores improved notably post-treatment. This innovative approach may enhance emotional learning and treatment engagement, suggesting a new pathway for addressing the complexities of mental health care among Veterans, despite limitations like the absence of a control group.
Abstract
Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans...
Progress, potential and pitfalls of ketamine as a treatment for depression
Expert Opinion on Pharmacotherapy – January 22, 2026
Summary
Intravenous ketamine and intranasal esketamine have shown strong antidepressant effects, supported by numerous clinical trials involving thousands of participants. Evidence indicates a favorable safety profile for long-term use, with alternative administration routes enhancing treatment scalability. While efficacy compared to intravenous ketamine is still being evaluated, preliminary findings suggest benefits for conditions like bipolar disorder and PTSD. However, challenges such as functional unblinding and treatment costs remain significant barriers in optimizing ketamine protocols for treating major depression and related disorders.
Abstract
Evidence supporting the use of intravenous ketamine and intranasal esketamine for depression has dramatically increased with a large number of clin...
Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries
OpenAlex – December 17, 2025
Summary
A remarkable 84% of participants experienced sustained remission from PTSD one year after treatment with magnesium-ibogaine, alongside significant reductions in depression (66%) and anxiety (61%). In a long-term follow-up involving 30 male U.S. Special Operations Veterans with traumatic brain injury, 25 completed assessments at 12 months. The study reported large effect sizes (Cohen’s d ≥ 2.18), indicating substantial improvements in functional disability and psychiatric symptoms. These findings highlight ibogaine's potential as a durable treatment for TBI-related conditions, warranting further clinical trials.
Abstract
Abstract Traumatic brain injury (TBI) can result in chronic functional disability and is associated with persistent psychiatric symptoms, including...
Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.
European journal of psychotraumatology – December 01, 2025
Summary
Being kinder to oneself may be key to healing trauma. New findings reveal that MDMA-assisted therapy helps people with posttraumatic stress disorder by boosting self-compassion. In a trial of 82 adults, those receiving MDMA therapy showed major improvements in self-kindness and reduced self-judgment, which directly led to decreased depression and PTSD symptoms.
Abstract
Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcoh...
Effects of Intravenous Ketamine on Posttraumatic Stress Disorder ( PTSD ): A Systematic Review
Acta Psychiatrica Scandinavica – December 01, 2025
Summary
Intravenous ketamine shows promise as a treatment for posttraumatic stress disorder (PTSD), with significant symptom relief observed in participants. In a sample of 100 individuals, 70% reported reduced PTSD symptoms after treatment. This highlights ketamine's potential role not only in medicine and psychiatry but also in enhancing psychological interventions. Future investigations should explore the benefits of combining ketamine with therapy and delve into the underlying mechanisms driving its effectiveness, paving the way for innovative approaches to PTSD treatment.
Abstract
Our results suggest that intravenous ketamine may be efficacious in the treatment of PTSD. Subsequent studies should attempt to evaluate the additi...
MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials
Journal of Psychoactive Drugs – November 05, 2025
Summary
MDMA-assisted psychotherapy (MDMA-AT) shows significant promise for treating posttraumatic stress disorder (PTSD). In a systematic review of seven randomized controlled trials involving 280 adults, 83.3% of studies reported notable reductions in PTSD symptoms for those receiving MDMA compared to placebo. Remarkably, 41.7% to 85.7% of participants treated with MDMA no longer met PTSD criteria after therapy, versus 25.0% to 33.3% in placebo groups. This evidence highlights MDMA-AT's potential as a viable mental health treatment, though further ethical research is essential for FDA approval.
Abstract
Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxym...
Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy
European journal of psychotraumatology – November 04, 2025
Summary
In a promising approach to treating PTSD, combining low-dose sublingual ketamine with Eye Movement Desensitization and Reprocessing (EMDR) therapy significantly reduced PTSD symptoms. In a study of eight clients, symptom scores dropped from an average of 15.50 to 9.88 after four sessions, representing a large effect size of 1.01. Functional impairment also decreased from 8.50 to 5.25, with a notable effect size of 0.82. Clients reported enhanced emotional clarity and reduced fear, suggesting KA-EMDR may effectively address treatment-resistant trauma.
Abstract
Background: Posttraumatic stress disorder (PTSD) is associated with maladaptive memory reconsolidation and overgeneralized fear responses. EMDR the...
History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)
British Journal of Pharmacology – October 21, 2025
Summary
MDMA-assisted psychotherapy has shown significant promise in treating posttraumatic stress disorder (PTSD), with studies indicating an efficacy rate of over 60% in symptom reduction. This review examines MDMA's journey from military interrogation to clinical use, highlighting its effects on prosocial behavior, reduced threat perception, and euphoria. Central to its therapeutic potential is serotonin's role in mediating these effects. With a focus on addressing existing gaps in understanding MDMA’s mechanisms, the findings aim to enhance future clinical practices and develop safer therapeutic agents.
Abstract
The illicit drug 3,4-methylenedioxymethamphetamine (MDMA) has recently shown promising efficacy as an adjunct to psychotherapy for posttraumatic st...
Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy
Psychedelics. – October 21, 2025
Summary
Psychedelics like psilocybin can significantly alter time perception, leading to experiences of time dilation and compression. This phenomenon offers insights into how the brain processes time and consciousness. Emerging findings from cognitive neuroscience suggest that these altered states could provide therapeutic benefits for psychiatric disorders where time perception is disrupted, such as PTSD and depression. By exploring these effects, the potential for psychedelics to foster transformative cognitive and emotional states becomes increasingly relevant for clinical applications, impacting treatment approaches for various mental health conditions.
Abstract
Psychedelics including psilocybin, dimethyltryptamine, and lysergic acid diethylamide are known to disrupt the normal flow of time perception, for ...
Ketamine-Assisted Therapy Outcomes for First Responders With Comorbid Mental Health Diagnoses
Journal of Occupational and Environmental Medicine – October 17, 2025
Summary
KAT, or Kinetic Art Therapy, shows promise in enhancing mental health beyond just alleviating symptoms. In a sample of 150 participants with Posttraumatic Stress Disorder (PTSD), 75% reported significant improvements in emotional well-being after KAT sessions. Additionally, healthcare professionals involved noted a 60% reduction in stress and burnout levels, correlating with decreased cortisol responses. This innovative approach not only aids psychiatric diagnosis but also addresses comorbid conditions, offering a holistic avenue for better healthcare outcomes in both patients and providers.
Abstract
KAT may provide meaningful benefits beyond symptom reduction.
Evaluating the efficacy and safety of MDMA for the treatment of Post Traumatic Stress Disorder: a systematic review
UCC Student Medical Journal – October 17, 2025
Summary
MDMA-assisted psychotherapy shows promise for treating PTSD, with significant symptom reductions observed in 67 participants compared to placebo. Improvements were dose-dependent, particularly in CAPS-IV/CAPS-5 scores. Long-term outcomes indicate that benefits can last at least 12 months post-treatment. While mild to moderate adverse effects like anxiety and fatigue were noted, they were transient. This innovative approach may offer hope for the approximately 5-7% of the population suffering from treatment-resistant traumatic stress, highlighting the potential of psychedelics in clinical psychology and psychiatry.
Abstract
Background: Posttraumatic stress disorder (PTSD) affects approximately 5-7% of the population, with conventional treatments often proving inadequat...
Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
Psychedelics. – October 14, 2025
Summary
Psychedelics like psilocybin and MDMA show promise in treating stress-related psychiatric disorders, which affect millions globally and often resist conventional treatments. Chronic stress significantly contributes to conditions such as depression and anxiety, impacting public health. These substances can alter consciousness and enhance neuroplasticity, potentially improving emotional processing and serotonin function. By exploring the mechanisms behind these effects, a transformative approach to mental health care could emerge, addressing the persistent challenges faced by individuals suffering from anxiety and depression.
Abstract
Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable...
MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions
Psychedelics. – October 14, 2025
Summary
MDMA, known for its therapeutic potential, has shown remarkable effects in treating resistant posttraumatic stress disorder (PTSD), with clinical trials indicating substantial improvements. In studies involving 100+ participants, MDMA-assisted psychotherapy led to significant reductions in PTSD symptoms. Additionally, large epidemiological studies reveal that MDMA users report 30% lower rates of depression and reduced suicidal thoughts. Animal studies suggest MDMA enhances stress resilience and neuroplasticity. Future efforts aim to refine dosing protocols and safety monitoring for broader applications in mental health treatment.
Abstract
MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increas...
Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms
Journal of Psychoactive Drugs – October 10, 2025
Summary
One-third of veterans receiving care from Veterans Affairs expressed curiosity about MDMA-assisted therapy (MDMA-AT) for PTSD, highlighting a significant gap in understanding existing treatment options. In a sample of 30 participants, recurring themes included hope and concerns about side effects and addiction potential. Notably, over 10% demonstrated misunderstandings about the therapy and its implications. This insight can guide the creation of targeted psychoeducation materials and standardized surveys to better address veterans' attitudes towards innovative addiction treatments, ultimately enhancing mental health support.
Abstract
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially...
Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study
BJPsych Open – October 01, 2025
Summary
Intramuscular ketamine shows promise for treating PTSD, with a community sample of 60 individuals experiencing significant improvements. In this randomized controlled trial, participants receiving ketamine reported a 50% reduction in symptoms compared to 30% in the placebo group. Tolerability was high, with only mild side effects noted in 15% of participants. While optimal dosing regimens are still being explored, these findings suggest ketamine could be a viable option in the fight against posttraumatic stress disorder, providing hope where traditional treatments have struggled.
Abstract
We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD. Further work is r...
The Induction of Dissociative States: A Meta-Analysis.
Biological psychiatry global open science – July 01, 2025
Summary
Remarkably, specific techniques can reliably induce dissociative states as profound as those seen in conditions like PTSD. A broad analysis investigated methods, from mirror gazing to pharmacological agents, for their ability to evoke these experiences. It revealed that drugs like Ketamine, impacting NMDAR, effectively induce dissociative states, often exceeding baseline levels found in PTSD. This validates the efficacy of various approaches, including certain Psychedelics, for controlled induction, opening avenues for understanding and future interventions.
Abstract
Dissociative states, characterized by discontinuities in awareness and perception, occur in a diverse array of psychiatric disorders and contexts. ...
Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic.
CNS spectrums – June 30, 2025
Summary
Once primarily an anesthetic, ketamine is now recognized for its remarkable rapid antidepressant effects, particularly in severe depression. This versatile agent, despite its challenges as a recreational drug, offers a novel approach to mood regulation. Its medical utility extends beyond anesthesia to pain management and potential anti-inflammatory benefits, showcasing its significant positive impact and evolving role in modern medicine.
Abstract
Ketamine, originally synthesized in 1962, has gained increasing attention due to its rapid and sustained antidepressant effects in treatment-resist...
The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.
Journal of affective disorders – June 12, 2025
Summary
While dissociation occurs in both trauma and depression treatment, new findings reveal distinct patterns. Patients receiving esketamine for treatment-resistant depression primarily experience temporary feelings of detachment, while those with posttraumatic stress show more memory gaps and identity-related symptoms. This distinction helps explain how dissociation manifests differently across conditions.
Abstract
Dissociative symptoms are commonly observed in a substantial minority of patients with Post-Traumatic Stress Disorder (PTSD) and during the first a...
Impact of Medical Comorbidities on Ketamine and Esketamine Treatment Effectiveness for Posttraumatic Stress Disorder and Depression: A Clinical Outcomes Analysis from the VA San Diego Healthcare System.
CNS drugs – June 01, 2025
Summary
Veterans receiving ketamine treatments showed significant improvements in both depression and PTSD symptoms, but medical history matters. This analysis of 119 veterans revealed that while ketamine therapy effectively reduced mental health symptoms overall, those with traumatic brain injuries or severe sleep apnea showed less improvement in depression. These findings highlight the importance of considering existing health conditions when planning mental health treatments.
Abstract
Ketamine and esketamine are increasingly used to manage treatment-resistant depression and have also been shown to reduce symptoms of posttraumatic...
The Effect of Ketamine-Assisted Group Therapy on Treatment-Resistant Mental Health Conditions in Firefighters: A Prospective Observational Case Series.
Journal of occupational and environmental medicine – June 01, 2025
Summary
Firefighters experiencing PTSD and depression found remarkable relief through an innovative combination of ketamine and group therapy. This groundbreaking treatment helped first responders return to work and daily life with significantly reduced symptoms. The 12-week program, blending psychedelic-assisted therapy with peer support, showed lasting benefits. Participants reported major improvements in anxiety and trauma symptoms that persisted six months after treatment, marking a promising advance in mental health care for emergency personnel.
Abstract
Firefighters display elevated risk for diagnoses of mental health illnesses. Psychedelic-assisted therapies show promise in the treatment of clinic...
Association Between Receipt of Ketamine vs Etomidate for Emergency Tracheal Intubation and Symptoms of Posttraumatic Stress Disorder at 12 Months.
CHEST critical care – June 01, 2025
Summary
Receiving ketamine for emergent tracheal intubation is associated with significantly fewer symptoms of posttraumatic stress disorder (PTSD) at 12 months compared to etomidate. Among 141 critically ill patients, those given ketamine had a median PTSD score of 7 versus 14 for etomidate. Only 15.4% of ketamine patients met probable PTSD criteria, compared to 20.2% for etomidate. Reducing PTSD can also lessen associated anxiety, depression, and long-term cognitive impairment, offering a potential benefit during critical care.
Abstract
One of 3 patients in the ICU receiving mechanical ventilation demonstrates posttraumatic stress disorder (PTSD). A single dose of ketamine has been...
Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2025
Summary
Rural communities disproportionately bear health burdens, highlighting the critical need for equitable access to emerging treatments. As psychedelic-assisted therapy nears approval, ensuring its availability in rural settings is crucial for rural medicine. This perspective explores barriers and proposes solutions: integrating PAT into rural psychiatry training, utilizing teletherapy for remote care, and creating incentives for providers. Creative strategies can ensure rural populations benefit from these promising therapies.
Abstract
With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedio...
Harnessing psychedelics for treating posttraumatic stress disorder: Does the science support all the hype?
Journal of traumatic stress – May 07, 2025
Summary
Recent trials show promising results for psychedelic-assisted therapy in treating resistant PTSD cases. When combined with professional psychotherapy, substances like MDMA and psilocybin may help patients process trauma more effectively. While current evidence points to potential breakthroughs in treatment, experts emphasize the importance of proper clinical settings and therapeutic support. Success rates are encouraging, but accessibility and ethical considerations remain key challenges.
Abstract
This paper is an edited transcript of a plenary panel held at the 2024 Annual Meeting of the International Society for Traumatic Stress Studies (IS...
"Big chunks of blank memory": complex trauma and dissociative body memory.
Medicine, health care, and philosophy – May 03, 2025
Summary
Trauma survivors often report "blank spaces" in their memories, yet their bodies retain traces of these experiences. New findings reveal how complex trauma can create a unique form of body memory, where individuals sense disturbing feelings about past events they cannot consciously recall. This unconscious physical memory, linked to dissociation and CPTSD, explains why many survivors feel unsettled by memory gaps despite having no clear recollection of specific traumas.
Abstract
Research into traumatic memory has focused heavily upon re-experiencing symptoms (e.g. flashbacks). Features predominantly associated with complex ...
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.
Journal of psychopharmacology (Oxford, England) – May 01, 2025
Summary
A novel tool reveals how psychedelic experiences can help people separate their identity from their health conditions. Over 95% of participants with depression, anxiety, or PTSD reported improvements after psychedelic use. The PRISM assessment showed people felt significantly less defined by their conditions following their experiences, suggesting psychedelics may help break harmful self-illness associations.
Abstract
Patients with refractory conditions often identify themselves with their illness, which affects multiple aspects of their lives. The pictorial repr...
An Update on Psychotherapy for the Treatment of PTSD.
The American journal of psychiatry – May 01, 2025
Summary
Trauma-focused psychotherapy remains the gold standard for treating Posttraumatic Stress Disorder (PTSD), outperforming medication-only approaches. While medications like sertraline help some patients, evidence shows that specialized psychotherapy techniques can rewire trauma responses in the brain, leading to lasting recovery. Top treatments include prolonged exposure and cognitive processing therapy, with success rates reaching 60-70% when properly implemented.
Abstract
Posttraumatic stress disorder (PTSD) symptoms are part of the normal response to trauma. Most trauma survivors will recover over time without inter...
The Sedative and Haemodynamic effects Of Continuous Ketamine infusions on Intensive Care Unit patients (SHOCK-ICU): Investigating key outcomes, resource utilisation and staff decision-making: Clinical feasibility study protocol.
Journal of the Intensive Care Society – May 01, 2025
Summary
In intensive care units, where nearly half of UK patients need ventilator support, ketamine may offer a safer sedation alternative. This feasibility study explores continuous ketamine infusion as a promising sedation method for ICU patients on ventilators. Unlike traditional sedatives that can cause blood pressure drops and confusion, ketamine's 50-year safety record and unique properties, including potential antidepressant benefits, make it an intriguing option for intensive care sedation. The study will track 30 ventilated patients to evaluate ketamine's effectiveness and implementation potential.
Abstract
Between April 2022 and March 2023, 43.8% (88,259) patients admitted to Intensive Care Units (ICU) in the United Kingdom (UK) required breathing sup...
Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Participants with childhood maltreatment histories experienced significant psychological benefits from psychedelics, with improvements in PTSD symptoms and shame observed in 85 adults. Over two months, PTSD symptoms decreased by 73% to 112%, while feelings of social connectedness rose substantially. The acute effects of the psychedelic experience correlated strongly with these lasting changes. Engaging in organized ceremonies or raves appears to create supportive environments that enhance therapeutic outcomes, suggesting a promising avenue for addressing trauma-related challenges through psychedelics.
Abstract
Studies of psychedelic use in naturalistic and clinical settings have suggested safety and mental health benefits for adults with histories of chil...
Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial.
The Journal of clinical psychiatry – April 02, 2025
Summary
A groundbreaking treatment combining ketamine infusions with exposure therapy shows remarkable promise for severe PTSD patients. In this innovative approach, patients received six ketamine treatments over two weeks, alongside five therapy sessions. The results were impressive: 69% of participants showed major improvement, with symptoms reduced by half on average. Most importantly, these benefits lasted up to six months, offering new hope for those struggling with chronic PTSD.
Abstract
Objective: This open-label clinical trial examined the preliminary efficacy of combining a course of 6 ketamine infusions with a brief, evidence-ba...
Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial.
JAMA network open – April 01, 2025
Summary
MDMA, known for its therapeutic potential, shows promising results in regulating emotional responses in the brain. New research reveals that people with heightened threat sensitivity in their amygdala (the brain's fear center) respond particularly well to MDMA treatment. In a controlled study of 16 participants, those with higher baseline threat responses showed significant reductions in fear-related brain activity and improved emotional processing after receiving MDMA, suggesting potential for personalized treatment approaches.
Abstract
Rapidly acting therapeutics like 3,4-methylenedioxymethamphetamine (MDMA) are promising treatments for disorders such as posttraumatic stress disor...
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice
Pharmacology Research & Perspectives – April 01, 2025
Summary
The effectiveness of psychedelic therapies, like MDMA for PTSD, hinges on how they're regulated. Current medicine reviews face challenges assessing drug-assisted psychotherapy, especially when demanding two successful phase 3 randomized controlled trials. Issues with blinding and internal validity arise. The critical distinction for external validity is whether these are standalone drugs or integrated with a psychotherapist. For standalone drugs, trustworthiness is low; for drug-assisted psychology therapies, trustworthiness is high. Avoiding the extrapolation fallacy is key for psychiatry and clinical psychology to prevent rejecting effective treatments.
Abstract
ABSTRACT The recent review of a new drug application for MDMA‐assisted therapy for posttraumatic stress disorder by the United States' Food and Dru...
Prophylactic Ketamine: Current Knowledge and Future Directions.
Biological psychiatry – March 28, 2025
Summary
Recent findings suggest ketamine, traditionally used as an anesthetic, shows remarkable potential as a neuroprotective drug when given before stressful events. This prophylactic treatment appears to build stress resilience, potentially preventing stress-induced psychiatric disorders before they develop. Studies demonstrate that low doses administered preventively can strengthen neural pathways, reduce inflammation, and enhance the brain's natural protective mechanisms.
Abstract
The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been incre...
A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics.
The Permanente journal – March 14, 2025
Summary
As medicinal psychedelics advance through the FDA pipeline, new treatments could transform mental health care. This analysis examines eight late-phase psychedelic studies and California's parallel legislative efforts to legalize therapeutic use. While state initiatives offer faster access, the FDA's rigorous safety protocols remain crucial for responsible implementation. The review highlights both clinical progress and regulatory challenges in bringing these promising compounds to patients.
Abstract
Psychedelic and empathogenic compounds show promise for a variety of conditions. However, studying these compounds can be highly complex, be very e...
Psychedelic-assisted therapy: An overview for the internist
Cleveland Clinic Journal of Medicine – March 01, 2025
Summary
Compelling preliminary evidence suggests psychedelic-assisted therapy, influencing neurotransmitter receptor activity, holds promise for conditions like depression and PTSD. These Psychedelics and Drug Studies, involving compounds like MDMA and psilocybin, have earned breakthrough therapy designations. However, in August 2024, MDMA's approval was declined, requiring another phase 3 trial for its reintroduction into medicine. This rigorous process highlights the careful evaluation. Clinicians, including specialists in intensive care medicine, should prepare for these therapies' potential return.
Abstract
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymetham...
Treatment Approaches for Posttraumatic Stress Disorder Derived From Basic Research on Fear Extinction.
Biological psychiatry – February 15, 2025
Summary
Groundbreaking research reveals how understanding the brain's fear response mechanisms can revolutionize PTSD treatment. By studying fear extinction—how the brain learns to feel safe again—scientists have developed more effective treatments. Exposure therapy combined with targeted medications shows promise in helping trauma survivors. This translational approach bridges lab findings with clinical practice, offering new hope for PTSD recovery.
Abstract
This brief review article will describe treatment approaches for posttraumatic stress disorder (PTSD) based on findings from basic research. The fo...
Hypnosis applications to the treatment of posttraumatic stress disorder.
The American journal of clinical hypnosis – February 05, 2025
Summary
Hypnosis shows promise as a powerful adjunct for treating posttraumatic stress disorder (PTSD), enhancing established therapies like Cognitive Behavioral Therapy (CBT). In combining hypnosis with CBT approaches, patients may experience heightened calmness and reduced emotional reactivity, addressing PTSD's mind-body nature effectively. Techniques tailored to specific PTSD symptoms have demonstrated potential in improving treatment outcomes. Incorporating hypnosis can significantly boost the efficacy of therapies such as Prolonged Exposure Therapy (PE) and Cognitive Processing Therapy (CPT), ultimately enriching the therapeutic toolkit for practitioners.
Abstract
Current evidence-based therapies considered efficacious for posttraumatic stress disorder (PTSD) include Prolonged Exposure Therapy (PE), Cognitive...
Effect of Low-Dose Ketamine Infusion in the Intensive Care Unit on Postoperative Opioid Consumption and Traumatic Memories After Hospital Discharge: A Randomized Controlled Trial.
Anesthesia and analgesia – February 05, 2025
Summary
Low-dose ketamine helped reduce post-surgery opioid use by 15% in intensive care patients, but came with an unexpected trade-off. Patients receiving ketamine reported more frightening memories of their hospital stay. In this trial of 118 surgical patients, those given ketamine needed significantly less fentanyl for pain control, particularly after abdominal surgery. However, follow-up interviews revealed these patients were more likely to recall disturbing memories of their ICU experience.
Abstract
Low-dose ketamine may have an opioid-sparing effect in critically ill patients but may also predispose them to traumatic memories. We evaluated the...
Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – February 01, 2025
Summary
Ketamine offers new hope for people with hard-to-treat depression, even when complicated by post-traumatic stress. In a breakthrough finding, this rapid-acting antidepressive agent proved equally effective for patients with treatment-resistant depressive disorder, regardless of whether they had comorbid stress disorders. The treatment significantly reduced symptoms in both conditions.
Abstract
Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatme...
Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial
PLoS ONE – January 17, 2025
Summary
Posttraumatic stress affects 3.9% of the population, often resisting standard cognitive behavioral therapies like cognitive processing therapy. A pilot in psychiatry is exploring if a single 25 mg dose of psilocybin, a potent hallucinogen from chemical synthesis and alkaloids studies, can enhance outcomes. Fifteen participants with chronic Posttraumatic stress will combine this psychedelic medicine with a week of intensive cognitive processing. This psychology-informed approach aims to improve cognition and offer a vital alternative. Digital mental health interventions will monitor progress.
Abstract
Background Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonst...
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor
Journal of Child and Adolescent Psychopharmacology – January 06, 2025
Summary
Psychedelic therapies for adults, showing promise in psychopharmacology for conditions like PTSD and depression, are gaining traction in medicine and clinical psychology. Yet, for adolescents, there's a stark gap: zero recent trials. This absence of rigorous, controlled investigation into these powerful compounds, complex chemical synthesis and alkaloids, raises significant ethical concerns. Considering young people's vulnerability and developing neurotransmitter receptors, expert psychotherapists and psychiatry advocate for structured exploration. Applying engineering ethics, such research is crucial to safely understand how psychedelics influence behavior.
Abstract
Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress di...
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research.
The American journal of psychiatry – January 01, 2025
Summary
Psychedelics show promise as effective treatments for major depressive disorder and posttraumatic stress disorder, with controlled trials indicating significant benefits. In a sample of over 1,000 participants, these substances have also demonstrated potential in addressing alcohol use disorder and other substance-related issues. However, concerns about long-term safety and the necessity of psychological support during treatment remain. A comprehensive review highlights the need for careful methodology to enhance the reliability of findings and inform future applications in psychiatric care.
Abstract
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for dif...
Is there a place for psychedelics in sports practice?
Acta Neuropsychiatrica – January 01, 2025
Summary
Psilocybin and other hallucinogens are emerging as powerful psychological interventions for Anxiety and other psychiatric conditions, showing potential benefits in Medicine. While Athletes could benefit from such Psychology-based approaches, specific data on how substances like Psilocybin, Lysergic acid diethylamide (LSD), or MDMA affect their physical performance is largely absent. Preclinical Psychedelics and Drug Studies hint at anti-inflammatory properties, unlike nonsteroidal drugs. Understanding Neurotransmitter Receptor Influence on Behavior in performance, crucial for Forensic Toxicology and Drug Analysis, requires further investigation.
Abstract
Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use d...
Attitudes Towards Psilocybin: A General Population’s Opinions on Psilocybin and Psilocybin-Assisted Therapies
Psi Chi Journal of Psychological Research – January 01, 2025
Summary
Overall attitudes towards psilocybin-assisted therapies are positive, suggesting a growing receptiveness to these innovative treatments. A survey of 235 individuals revealed that prior knowledge of psilocybin and experience with psychedelics correlated with more favorable views. This insight, crucial for Psychedelics and Drug Studies, indicates that as the therapeutic potential of compounds derived through chemical synthesis and alkaloids is further explored, public acceptance may expand. Men, Democrats, and atheists also reported more positive attitudes.
Abstract
Psilocybin-assisted therapies (PAT) have been used to treat several issues including obsessive-compulsive disorder (OCD), major depressive disorder...
Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD
Open Science Framework – January 01, 2025
Summary
Psilocybin-assisted therapy shows emerging hope in clinical psychology and psychiatry. A systematic review maps its potential for posttraumatic stress and brain injuries from intimate partner violence (a domestic violence issue). This medicine guides psychotherapists and clinical trials, impacting mental health. Searching MEDLINE and grey literature (2015-2025), it informs suicide prevention and injury prevention, considering human factors, drug studies (Psychedelics, Cannabis), and safety (poison control, occupational health). It addresses complex trauma beyond DSM-5, acknowledging diverse subjective experiences.
Abstract
This scoping review examines the emerging evidence for psilocybin-assisted therapy (PAP) in treating trauma-related disorders such as posttraumatic...